Efficacy of delayed granulocyte colony-stimulating factor after autologous BMT.
Granulocyte colony-stimulating factor (G-CSF) has been shown to be effective in accelerating neutrophil recovery after BMT. In this single centre study, we have examined the effect of delaying the start of treatment with G-CSF (5 micrograms/kg) until 8 days after BM infusion in a cohort of 17 patients with malignant lymphomas undergoing autologous BMT. In comparison with historical controls, neutrophil recovery to > 0.5 x 10(9)/l was shortened from 22 to 14 days (p < 0.01). Patients receiving G-CSF required iv antibiotics for a median 13 days (control 17, p < 0.05) and were discharged a median 28 days post-ABMT (control 32.5, p = NS). Patients received G-CSF for a median of 10 days only. Although these results require confirmation in a randomised trial they suggest that G-CSF administration could be delayed until 8 days after BMT without compromising efficacy and with an accompanying reduction in treatment costs.
Khwaja
A
A
Department of Haematology, University College London Medical School, UK.
Mills
W
W
Leveridge
K
K
Goldstone
A H
AH
Linch
D C
DC
D000328:Adult; D016470:Bacteremia / Q000188:drug therapy / Q000209:etiology; D016026:Bone Marrow Transplantation; D002452:Cell Count; D003131:Combined Modality Therapy; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000008:administration & dosage*; D006801:Humans; D008223:Lymphoma / Q000188:drug therapy / Q000628:therapy*; D008297:Male; D009504:Neutrophils / Q000187:drug effects / Q000473:pathology*; D016896:Treatment Outcome
D016179:Granulocyte Colony-Stimulating Factor